SCHEMBL5461249

SCHEMBL5461249

Cc1cc(C)cc(CN2C(=O)SC(=Cc3ccc(O)c(C(=O)O)c3)C2=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 8/20 0.59
▸ ACP1 P24666 8/20 0.59
▸ BAG3 O95817 1/20 0.53
▸ ENPP2 Q13822 3/20 0.50
▸ MEN1 O00255 2/20 0.48
▸ POLB P06746 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ CRHBP P24387 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ CRHR2 Q13324 1/20 0.48
▸ NOD2 Q9HC29 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ PTPN22 Q9Y2R2 1/20 0.48
▸ HSP90AA1 P07900 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ SENP8 Q96LD8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461246 1.00 PTPN1 (0.59) PTPN1ACP1BAG3ENPP2MEN1
SCHEMBL5470315 0.89 PTPN1 (0.56) PTPN1ACP1BAG3ENPP2MEN1
SCHEMBL5470321 0.89 PTPN1 (0.56) PTPN1ACP1BAG3ENPP2MEN1
SCHEMBL5463879 0.87 PTPN1 (0.60) PTPN1ACP1ENPP2MEN1POLB
SCHEMBL5466748 0.87 ENPP2 (0.58) PTPN1ACP1ENPP2MEN1POLB
SCHEMBL5463880 0.87 PTPN1 (0.60) PTPN1ACP1ENPP2MEN1POLB
SCHEMBL5466747 0.87 ENPP2 (0.58) PTPN1ACP1ENPP2MEN1POLB
SCHEMBL5462391 0.85 NLRP3 (0.62) PTPN1ACP1ENPP2PTPN22NLRP3
SCHEMBL5462396 0.85 NLRP3 (0.62) PTPN1ACP1ENPP2PTPN22NLRP3
SCHEMBL5462986 0.84 PTPN1 (0.65) PTPN1ACP1ENPP2MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PTPN1 3264/4885ACP1 254/4885BAG3 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback